Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial): a multicentre, randomized, open-label, non-inferiority trial.

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506187-14-00

Enrollment

Registered

2023-11-24

Start date

2024-01-12

Completion date

2026-01-09

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria

Brief summary

Absolute difference in average urticaria control test (UCT) score between treatment arms at week 36.

Interventions

DRUGXolair 150 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Absolute difference in average urticaria control test (UCT) score between treatment arms at week 36.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026